OTC Markets OTCQB - Delayed Quote USD

BioAtla, Inc. (BCAB)

2.1000 -0.0100 (-0.47%)

At close: October 30 at 3:51:10 PM EDT

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

BioAtla Announces Share Consolidation

GlobeNewswire 6mo ago

BCAB
-0.47%
^IXIC
BioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

GlobeNewswire 6mo ago

BCAB
-0.47%
BioAtla (BCAB) Q3 2025 Earnings Call Transcript

Motley Fool 11mo ago

BCAB
-0.47%
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202

GlobeNewswire 5mo ago

CNTX

BCAB
-0.47%
BioAtla Announces Formal Process to Evaluate Strategic Options to Monetize Assets

GlobeNewswire 7mo ago

BCAB
-0.47%
BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC)

GlobeNewswire 9mo ago

BCAB
-0.47%
BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing

GlobeNewswire 11mo ago

BCAB
-0.47%
BioAtla Inc (BCAB) Q3 2025 Earnings Call Highlights: Strategic Partnerships and Promising Trial ...

GuruFocus.com 11mo ago

BCAB
-0.47%
CNTX
BioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

GlobeNewswire 11mo ago

BCAB
-0.47%
CNTX
$BioAtla’s Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas$

BioAtla’s Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas

GlobeNewswire 11mo ago

BCAB
-0.47%

Performance Overview

Return	BCAB	S&P 500 (^GSPC)
YTD	-92.61%	+10.73%
1-Year	-93.96%	+11.11%
3-Year	-97.14%	+81.91%

U.S. markets closed

BioAtla, Inc. (BCAB)

BioAtla Announces Share Consolidation

BioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

BioAtla (BCAB) Q3 2025 Earnings Call Transcript

Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202

BioAtla Announces Formal Process to Evaluate Strategic Options to Monetize Assets

BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC)

BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing

BioAtla Inc (BCAB) Q3 2025 Earnings Call Highlights: Strategic Partnerships and Promising Trial ...

BioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

BioAtla’s Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas